Latest news with #profitmiss
Reuters
23-07-2025
- Business
- Reuters
Dr Reddy's kicks off India big pharma earnings with narrow profit miss
July 23 (Reuters) - Indian generic drugs maker Dr Reddy's Laboratories ( opens new tab posted a narrow miss of quarterly profit expectations on Wednesday, as it struggled with pricing pressure on drugs and stiff competition in its key North America market. The firm, one of the top three drugmakers in India by revenue, has been strengthening its consumer healthcare portfolio, which includes over-the-counter medicines, nutrition supplements, as it looks to build a strong pipeline of differentiated products beyond its generics business. Its total revenue rose 11.4% to 85.72 billion rupees ($992.21 million) in the June quarter, largely helped by an 11% rise in revenue from domestic business. Revenue from Reddy's biggest market North America fell 11.3% for the quarter. "The decline was primarily due to increased price erosion in certain key products including Lenalidomide," the company said in a statement. Lenalidomide, a generic version of Bristol-Myers Squibb's (BMY.N), opens new tab popular cancer treatment drug Revlimid, has been a key contributor to the company's North America sales since 2022. But Revlimid's patent expiry in 2026 would pave way for more number of players in the market, hurting demand for Dr Reddy's products. Delayed approvals for new drug applications, pricing pressure in the U.S. have been impacting the drugmakers' growth in the market. Revenue from Europe more than doubled, driven by demand for nicotine replacement therapy, which Dr Reddy's bought from British drugmaker Haleon (HLN.L), opens new tab in 2024. Dr Reddy's consolidated net profit increased to 14.18 billion rupees in the quarter ended June 30, below analysts' estimate of 14.94 billion rupees, as per data compiled by LSEG. Rival Cipla ( opens new tab is set to report first quarter results on Friday. ($1 = 86.3930 Indian rupees)
Yahoo
22-07-2025
- Business
- Yahoo
Why Lockheed Martin Stock Is Falling Today
Key Points One-time charges led to a significant profit miss. Lockheed Martin still has a solid business, but there are few immediate catalysts. 10 stocks we like better than Lockheed Martin › Lockheed Martin's (NYSE: LMT) quarter was loaded with cost overruns and write-offs, causing the defense contractor to miss expectations. Investors were disappointed, sending Lockheed shares down more than 5% as of 10:30 ET Tuesday. Charges eat into results Lockheed Martin ranks as the world's largest defense contractor, but the company has come on hard times of late. The maker of the F-35 and a wide range of helicopters, missiles, and space systems has been shut out of recent high-profile awards, including the new fighter jet program that went to Boeing. Lockheed shares are down about 14% from their peak for the year. The company's latest results are not helping reverse the momentum. Lockheed earned $1.46 per share in the quarter on revenue of $18.2 billion, missing Wall Street's consensus estimate for $6.52 per share in earnings on revenue of $18.6 billion. There is a lot of noise in that earnings number. Quarterly results included $1.6 billion in program losses including $950 million on a classified aerospace project. Absent those charges, earnings would have come in at $7.29 per share. Free cash flow was also soft. Lockheed used $150 million in cash, compared to an estimate for $1.2 billion in positive free cash flow, thanks to slower-than-expected F-35 deliveries. Is Lockheed Martin stock a buy? The charges were mostly one-time items, but unfortunately for investors there is no reason to believe things will improve anytime soon. Lockheed's book-to-bill, a measure of future business compared to current-quarter revenue, was an anemic 0.8x, with none of the company's four segments booking more business in the quarter than what they billed out. Lockheed Martin remains a powerful franchise that should find new opportunities over time. But for now, investors are likely to have to be content with a 3% dividend yield as Lockheed works through these headwinds. Do the experts think Lockheed Martin is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Lockheed Martin make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,055% vs. just 180% for the S&P — that is beating the market by 874.27%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $665,092!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,477!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Lou Whiteman has positions in Lockheed Martin. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy. Why Lockheed Martin Stock Is Falling Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
